Telehealth Weight Loss/GLP-1 Prescribing: What Prescribers Can Do in Michigan

Last updated: July 7, 2026

If you’re a psychiatrist or PMHNP wondering whether prescribing GLP-1s or other weight-loss medications fits within your scope—or whether it’s even legal in your state—you’re not alone. The explosive demand for medications like Wegovy, Ozempic, and Mounjaro has blurred the traditional lines between psychiatry and metabolic medicine. And for good reason: many of your patients struggle with obesity, often worsened by the very medications you prescribe.

Here’s the reality: Yes, psychiatrists can prescribe weight-loss medications—and in many cases, they should. But the rules vary wildly by state, provider type, and whether you’re practicing via telehealth. This guide breaks down the scope-of-practice considerations, state-specific regulations, reimbursement realities, and what it actually means for your practice.

Why Psychiatrists Are Entering the Weight Management Space

Let’s start with the clinical rationale. If you’re treating patients on antipsychotics, mood stabilizers, or even some antidepressants, you’ve seen the metabolic fallout: weight gain, insulin resistance, dyslipidemia. For years, psychiatrists monitored these side effects but often felt limited in what they could do beyond referring patients to primary care or endocrinology.

Enter GLP-1 receptor agonists. Originally developed for Type 2 diabetes, drugs like semaglutide and tirzepatide have proven remarkably effective for weight loss—and they’re showing promise beyond the scale. Research suggests potential benefits for mood regulation, reduced cravings in substance use disorders, and improved quality of life independent of weight loss alone.

Dr. Elliott Lewis, a board-certified psychiatrist and obesity medicine specialist, frames it this way: ‘If we truly understand that metabolic and mental health systems are inseparable, then psychiatrists being involved in metabolic treatment makes complete sense.’ He’s not talking about psychiatrists abandoning their core work—he’s talking about integrated care for patients whose obesity and mental health are intertwined.

The competency question is legitimate. Traditionally, psychiatrists haven’t been trained in nutrition science or metabolic disorders. But many are pursuing additional certification—the American Board of Obesity Medicine (ABOM) now certifies physicians of any specialty, including psychiatry, who complete ~60 hours of obesity-focused CME and pass a comprehensive exam. This isn’t ‘scope creep’—it’s evidence-based expansion of what holistic psychiatric care can look like.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Psychiatrists vs. PMHNPs: Who Can Prescribe What, Where

Psychiatrists (MD/DO): Full Authority, With State-Specific Guardrails

As a physician, you have the broadest prescriptive authority in all 50 states. Your DEA license and state medical license cover FDA-approved weight-loss medications—both controlled (like phentermine, Schedule IV) and non-controlled (GLP-1 agonists, orlistat, etc.).

But—and this is critical—state medical boards impose specific clinical standards for obesity treatment. These aren’t optional guidelines; they’re enforceable rules.

Take Florida, for example. The Board of Medicine requires:

• Documented BMI ≥30 (or ≥27 with comorbidities) before prescribing any anti-obesity medication
• A comprehensive physical exam and history prior to treatment
• Written informed consent discussing risks and benefits
• Follow-up visits at least every 3 months to continue treatment
• Delivery of the state’s ‘Weight-Loss Consumer Bill of Rights’ to patients

Florida allows telehealth for these visits, but the clinical thoroughness can’t be shortcut. You must document vital signs, review labs (TSH, glucose, lipids), and rule out secondary causes of obesity. The state explicitly allows APRNs or PAs to conduct the initial evaluation under physician delegation—but someone must do it properly.

New Jersey goes further, requiring comprehensive psych screening before prescribing weight-loss meds and mandating that prescribers provide or arrange nutritional counseling, exercise recommendations, and behavior modification—not just pills. For psychiatrists, this is actually a strength: you’re already trained to assess and manage psychiatric comorbidities that might complicate weight loss (depression, binge eating, etc.).

Texas prohibits prescribing Schedule II stimulants for weight loss, but phentermine (Schedule IV) and GLP-1s are fair game with proper documentation. No special obesity treatment protocols exist beyond standard medical practice, but corporate practice of medicine rules mean you’ll likely need a proper entity structure if you’re starting a weight-loss service line.

Bottom line for psychiatrists: You can prescribe these medications anywhere, but you must follow state-specific treatment standards and document appropriately. The days of quick ‘diet pill’ prescribing are over—boards are watching.

PMHNPs: State-by-State Maze

If you’re a psychiatric nurse practitioner, your prescribing authority for weight-loss medications depends entirely on where you’re licensed.

Full Practice Authority (FPA) States (~24 states + D.C.): You can prescribe weight-loss medications independently, including controlled substances in most cases, without physician oversight. Examples: Washington, Oregon, Arizona, New Mexico, Colorado, Maryland, Connecticut. You’ll still need appropriate training and should follow the same clinical standards as MDs, but you don’t need a collaborative agreement.

Reduced Practice States (where collaboration is required for prescribing): You’ll need a written agreement with a physician. Examples include:

• New York: After 3,600 hours of practice, you can work independently, but you’ll need protocols for controlled substances initially
• Illinois: With ≥4,000 hours of experience and additional CE, you can obtain Full Practice Authority and prescribe independently (including controlled substances with some initial physician consultation requirements)
• Pennsylvania: You must have a collaborative agreement with a physician whose name appears on your prescriptions. The agreement must specify which drug categories you can prescribe, including weight-loss meds

Restricted Practice States (tight physician oversight required):

• Texas: All NPs must have a Prescriptive Authority Agreement with a Texas physician. The agreement requires monthly face-to-face meetings, chart reviews, and explicit delegation of what you can prescribe. You cannot practice independently—period.
• Florida: APRNs must practice under physician protocols. Even Florida’s ‘autonomous practice’ law (limited to primary care NPs, not psych) excludes controlled substance prescribing. For weight-loss work, you’ll need an MD supervisor and written protocols covering obesity treatment.

California is in transition: AB 890 allows experienced NPs to practice independently after 3 years/4,600 hours under physician supervision. Full implementation hits January 2026. But California’s Corporate Practice of Medicine doctrine still requires physician ownership or medical director oversight for clinics, even if individual NPs achieve independence.

The practical reality: Even in FPA states, some insurers and pharmacies push back on high-cost GLP-1 prescriptions from NPs without physician co-signature. It’s not a legal requirement, but it’s a real-world friction point. Many telehealth platforms maintain physician medical directors in every state to smooth insurance credentialing and provide oversight for controlled substances—smart business, even where not legally required.

Telehealth Prescribing: Federal Green Light, State Red Lights

The federal DEA extended COVID-era telehealth flexibilities through December 31, 2025, allowing providers to prescribe controlled substances via telemedicine without an initial in-person exam. Great news, right?

Not so fast. Federal waivers don’t override state law. And several states have erected hard barriers to remote controlled-substance prescribing.

States That Prohibit Telehealth Prescribing of Controlled Weight-Loss Drugs

Florida: State law flatly bans prescribing controlled substances via telehealth except for psychiatric disorder treatment, inpatient/hospice care, or acute pain/addiction treatment. Weight loss isn’t on that list. That means you cannot prescribe phentermine via telehealth to Florida patients, even though federal law technically allows it. GLP-1s? Fine, because they’re not controlled. But phentermine is off the table unless you have an in-person visit.

Alabama: Requires an initial in-person exam (or physician physically present) before prescribing any controlled substance. No telemedicine workaround.

South Carolina, Idaho, Louisiana: Similar restrictions—telehealth alone won’t cut it for controlled diet drugs.

About 8 states maintain telehealth prescribing restrictions stricter than current federal rules. If you’re building a national telehealth weight-loss practice, you’ll need to geofence or arrange local in-person exams in these states.

For Non-Controlled Medications (GLP-1s)

Most states allow prescribing via telehealth as long as you establish a valid provider-patient relationship and meet standard-of-care requirements. This typically means:

• A live video consultation (audio-only is risky for initial visits)
• Comprehensive history and visual exam
• Documentation of vitals (many telehealth platforms have patients submit weight, BP readings)
• Ordering appropriate labs (glucose, TSH, lipids—can be done locally)
• Informed consent and treatment planning

Florida’s obesity rules require an ‘appropriate physical examination’ but don’t mandate in-person—the state allows APRNs to conduct evaluations under delegation, suggesting a thorough telehealth exam can suffice. But borderline cases get providers in trouble. A Mississippi doctor lost his license in 2023 for prescribing Ozempic via text message with no video or audio contact. Don’t be that person.

Best practice: Initial consult via video, follow-ups can be video or phone depending on clinical need and state rules (Florida mandates at least quarterly follow-ups). Document everything—especially that you discussed risks, reviewed metabolic workup, and provided lifestyle counseling.

The Economics: What Weight-Loss Prescribing Means for Your Practice

Let’s talk money, because this matters for sustainability.

Insurance Reimbursement is Improving—Fast

A few years ago, weight-loss medications were mostly cash-pay. Medicare explicitly excluded them. Medicaid coverage was spotty. That’s changing.

Medicare will begin covering FDA-approved anti-obesity medications in 2026 following recent policy shifts and pharmaceutical pricing agreements. This is enormous—millions of Medicare beneficiaries will now have access to GLP-1s for obesity, creating massive patient demand.

Commercial insurers increasingly cover GLP-1s, but with strict criteria:

• Prior authorization requiring documented BMI ≥30 (or ≥27 with comorbidities)
• Evidence of lifestyle modification attempts
• Documentation that prescriber is providing comprehensive weight management (not just pills)
• Some insurers impose quantity limits—e.g., 30-day supply initially to monitor adherence

State Medicaid programs vary. Illinois Medicaid, for example, covers obesity treatment and reimburses APRNs at 100% of physician rates (not the typical 85%). Many states are expanding coverage following the Medicare lead.

Visit Reimbursement

You’re billing standard E/M codes for medication management visits. A 20-minute follow-up for a patient on semaglutide would typically be coded as 99213 or 99214 (established patient, low-moderate complexity), reimbursing ~$75-$130 depending on region and payer.

Initial psychiatric evaluations with medication management (90792) can reimburse ~$200+ for psychiatrists. If you’re integrating obesity treatment into your psych practice (e.g., managing both depression and medication-induced weight gain), you’re documenting both problems and billing appropriately for complexity.

Telehealth parity laws in California, New York, Illinois, Pennsylvania, and many other states ensure that insurers pay the same rate for telehealth visits as in-person. Medicare continues reimbursing telehealth mental health visits at office rates through at least 2025, likely longer.

Psychiatrists get 100% of physician fee schedules. PMHNPs typically get 85% from Medicare and many commercial payers, though states like Illinois are closing that gap.

What About Patient Acquisition Cost?

Here’s where provider platforms like Klarity Health change the math entirely.

DIY marketing for a weight-loss practice is expensive and uncertain:

• SEO takes 6-12 months of consistent investment before generating meaningful patient flow
• Google Ads for ‘weight loss doctor’ or ‘GLP-1 prescription’ run $15-40+ per click, with most clicks not converting to booked patients
• Realistic cost per booked patient through PPC: $200-400+ when you factor in wasted spend, testing, and optimization
• Directory listings (Psychology Today, Zocdoc) charge monthly fees AND you compete with hundreds of other providers on the same page
• Even Zocdoc’s per-booking model ($35-100 per appointment) adds up when you include the monthly subscription

All-in, providers trying to build their own weight-loss patient base through marketing spend $3,000-5,000+ monthly with no guaranteed results. That’s fine if you have deep pockets and patience—but for most providers, especially those starting out or scaling, it’s a gamble.

Klarity’s model is fundamentally different: You pay a standard listing fee per new patient lead who books with you. No upfront marketing spend. No monthly subscriptions. No wasted ad budget on clicks that don’t convert.

The value proposition:

• Pre-qualified patients already matched to your specialty and availability
• Both insurance and cash-pay patient flow (increasingly insurance as coverage expands)
• Built-in telehealth infrastructure—no separate platform costs
• You control your schedule and only pay when you see patients
• Guaranteed ROI: Instead of gambling $4,000/month on marketing that might not work, you pay only when a qualified patient books

This is especially powerful for weight-loss medication management where patient demand is skyrocketing but acquisition costs through traditional channels are climbing. For a psychiatrist or PMHNP adding GLP-1 prescribing to their practice, a platform model removes all the patient acquisition risk while you focus on delivering excellent care.

State-Specific Compliance: What You Need to Know

California

• NP scope: Transitioning to FPA (full by Jan 2026), but Corporate Practice of Medicine still requires physician oversight for clinic structures
• Prescribing: No special obesity treatment rules; follow standard care. Check for compounding pharmacy compliance.
• Telehealth: Permissive—telehealth parity law in effect
• Bottom line: Great market, strong demand, watch for CPOM compliance if you’re building a service line

Texas

• NP scope: Strict delegation required. Written Prescriptive Authority Agreement, monthly MD meetings, chart reviews
• Prescribing: No Schedule II stimulants for weight loss. Phentermine (C-IV) and GLP-1s allowed with proper protocols.
• Telehealth: Allowed for weight-loss meds via federal waiver; check PMP for controlled substances
• Bottom line: Physician-led models required. High demand market but tightly regulated.

Florida

• NP scope: Physician protocols required (no PMHNP autonomy)
• Prescribing: Strict Board of Medicine rules—BMI documentation, informed consent, quarterly follow-ups mandatory
• Telehealth: Cannot prescribe controlled substances via telehealth for weight loss. GLP-1s are fine remotely.
• Bottom line: High regulatory scrutiny. Excellent market but stay compliant with clinic licensing and obesity treatment rules.

New York

• NP scope: Reduced practice; experienced NPs can work independently after 3,600 hours
• Prescribing: No specific obesity treatment rules; follow standard care and check PMP for controlled drugs
• Telehealth: Telehealth parity in effect; no extra prescribing restrictions
• Bottom line: Progressive telehealth environment, strong reimbursement, watch for AG scrutiny on advertising

Pennsylvania

• NP scope: Collaborative agreements required; physician name must appear on prescriptions
• Prescribing: Standard medical practice; collaboration agreement should specify weight-loss drug authority
• Telehealth: Telehealth visits reimbursed; no special restrictions
• Bottom line: Collaboration can be barrier in rural areas but manageable. Advocacy for FPA ongoing.

Illinois

• NP scope: FPA available after 4,000 hours + CE; independent prescribing including controlled substances
• Prescribing: No special state obesity rules; use standard guidelines
• Telehealth: Strong parity laws; Medicaid reimburses APRNs at 100% of physician rates
• Bottom line: One of the most NP-friendly states. Great opportunity for experienced PMHNPs.

Should You Do This? The Practical Considerations

Add weight-loss prescribing to your practice if:

• You’re already managing patients with medication-induced weight gain or comorbid obesity
• You’re willing to invest in competency (ABOM certification or focused CME in obesity medicine)
• You can integrate lifestyle counseling or partner with dietitians/health coaches to meet state standards
• You practice via telehealth and can navigate state-specific rules efficiently
• You want to offer more integrated care without referring patients out for every metabolic issue

Proceed cautiously if:

• You’re in a restricted state (Florida, Texas) and don’t have physician collaboration lined up
• You’re not prepared to follow stringent documentation requirements (quarterly follow-ups, informed consent, etc.)
• You’re thinking of prescribing purely for revenue without proper clinical training
• Your patient population doesn’t overlap with obesity treatment needs

Don’t do it if:

• You view it as a quick revenue grab without proper competency
• You’re in a state where telehealth controlled-substance prescribing is banned and you rely on phentermine
• You’re not willing to coordinate with primary care or order appropriate metabolic workup

The Bottom Line: An Opportunity, Not a Distraction

Weight-loss medication management isn’t about psychiatrists becoming obesity specialists or PMHNPs abandoning their core work. It’s about recognizing that the patients you’re already treating need comprehensive care—and sometimes that means addressing the 40-pound weight gain from olanzapine or the pre-diabetes developing on quetiapine.

The regulatory landscape is navigable if you do your homework. The reimbursement environment is improving rapidly with Medicare and commercial coverage expanding. And the patient demand is undeniable—GLP-1s are reshaping how we think about metabolic health.

For psychiatrists and PMHNPs on telehealth platforms, this represents a genuine opportunity to expand scope responsibly, increase income, and offer more integrated care. Just make sure you’re following your state’s rules, documenting appropriately, and practicing within your competency.

And if you’re looking to build this into your practice without the headache of marketing spend and patient acquisition uncertainty? Platforms like Klarity handle the patient flow while you focus on what you do best—delivering excellent clinical care.

Frequently Asked Questions

Can a psychiatrist legally prescribe Wegovy or Ozempic for weight loss?

Yes. Psychiatrists (MD/DO) have full prescriptive authority in all states for FDA-approved medications, including GLP-1 agonists like Wegovy (semaglutide for obesity) and off-label use of Ozempic (semaglutide for diabetes). However, some states like Mississippi have banned off-label prescribing of diabetes GLP-1s purely for weight loss—you must use the FDA-approved obesity version. Always follow state medical board obesity treatment rules (BMI criteria, documentation, follow-ups) and ensure you’re competent in obesity medicine through training or certification.

Do PMHNPs need physician supervision to prescribe weight-loss medications?

It depends on your state. In ~24 Full Practice Authority states (like Washington, Colorado, Connecticut), experienced PMHNPs can prescribe independently, including weight-loss drugs. In states requiring collaboration (Texas, Florida, Pennsylvania), you must have a written agreement with a physician who delegates prescribing authority for these medications. Even in FPA states, some insurers may request physician involvement for high-cost GLP-1 prescriptions. Check your state’s Nurse Practice Act for current requirements.

Can I prescribe phentermine via telehealth?

Federal law (via DEA extension through Dec 2025) allows it, but several states prohibit telehealth prescribing of controlled substances for weight loss. Florida explicitly bans controlled-substance prescribing via telehealth except for psychiatric disorder treatment, so phentermine (Schedule IV) cannot be prescribed remotely there. Alabama, Idaho, and Louisiana have similar restrictions. In states without specific bans (Texas, New York, Illinois), you can prescribe phentermine via telehealth as long as you establish a proper patient relationship, document appropriately, and check the state prescription monitoring program. Always verify your state’s current telehealth controlled-substance rules.

What are the documentation requirements for prescribing GLP-1s?

At minimum: documented BMI ≥30 (or ≥27 with obesity-related comorbidities like diabetes or hypertension), comprehensive history and physical exam findings (can be via telehealth video in most states), discussion of risks/benefits with informed consent, baseline labs (glucose, TSH, lipids), and a treatment plan including lifestyle modifications (diet, exercise). States like Florida require written informed consent and quarterly follow-up visits documented. New Jersey mandates psychiatric assessment and nutritional counseling arrangement. Always document your clinical rationale, monitoring plan, and patient education in the medical record to meet state board standards and support insurance billing.

Will insurance cover GLP-1 medications prescribed by a psychiatrist?

Increasingly, yes—but it requires prior authorization. Commercial insurers now cover FDA-approved obesity medications like Wegovy if patients meet criteria (typically BMI ≥30 or ≥27 with comorbidities) and you document lifestyle modification attempts. Medicare will begin covering anti-obesity medications in 2026. Medicaid coverage varies by state. The prescriber’s specialty (psychiatry vs. endocrinology) usually doesn’t matter for coverage—what matters is proper documentation of medical necessity and meeting the payer’s criteria. You’ll need to complete prior auth forms attesting to BMI, comorbidities, and comprehensive weight management plan. Expect 30-day supply limits initially from some insurers.

Is prescribing weight-loss medications within a PMHNP’s scope of practice?

Legally, if your state allows PMHNP prescribing (independently or under collaboration) and you have appropriate training/competency, yes. Scope of practice is defined by what you’re educated and competent to do, not rigidly by specialty. Many PMHNPs argue that managing obesity in psychiatric patients (especially medication-induced weight gain) is within holistic mental health care. However, running a standalone weight-loss clinic as a psych NP might draw scrutiny unless you have additional obesity medicine training. Safest approach: prescribe weight-loss meds as part of integrated care for patients you’re already treating psychiatrically, document your competency (CE courses, ABOM certification if pursuing), and ensure your collaborative agreement (where required) explicitly covers weight management prescribing.

References

1. MedicalDirector Co. (2025). ‘How Much Does a Collaborative Physician Cost for Weight Loss, Telehealth, and Medspas? (2025 Definitive Guide).’ https://www.medicaldirectorco.com/collaborative-physician-cost-weight-loss-telehealth/

2. MedicalDirector Co. (2025). ‘Florida Weight Loss Clinic and Telehealth Compliance Guide (2025).’ https://www.medicaldirectorco.com/florida-weight-loss-clinic-and-telehealth-compliance-guide-2025/

3. Florida Administrative Code Rule 64B15-14.004 (Effective Aug 8, 2022). ‘Standards for Prescription of Obesity Drugs.’ https://www.law.cornell.edu/regulations/florida/Fla-Admin-Code-Ann-R-64B15-14-004

4. Foley & Lardner LLP (July 24, 2023). ‘A Changing Regulatory and Reimbursement Landscape for Weight-Loss Drugs.’ Mondaq. https://www.mondaq.com/unitedstates/healthcare/1447512/a-changing-regulatory-and-reimbursement-landscape-for-weight-loss-drugs

5. RxAgent.co (Dec 16, 2025). ‘Federal Permission, State Prohibition: The 2026 Telehealth Compliance Trap.’ https://rxagent.co/blog/telehealth-compliance-trap

Source:

• https://www.medicaldirectorco.com/collaborative-physician-cost-weight-loss-telehealth/#:~:text=The%20answer%20is%20almost%20always,yes
• https://www.medicaldirectorco.com/collaborative-physician-cost-weight-loss-telehealth/#:~:text=Nurse%20Practitioners%20
• https://journals.lww.com/tnpj/fulltext/2024/01000/36thannualaprnlegislativeupdate__improving.6.aspx#:~:text=The%20Pennsylvania%20BON%20grants%20CRNPs%2C,more%20physicians%20to%20deliver%20healthcare
• https://journals.lww.com/tnpj/fulltext/2024/01000/36thannualaprnlegislativeupdate__improving.6.aspx#:~:text=The%20Illinois%20Department%20of%20Financial,collaborative%20agreement%20following%20a%20TTP
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20DEA%20gave%20us%20the,evaluation%20at%20the%20federal%20level
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=Despite%20federal%20DEA%20waivers%20extending,traps%20for%20digital%20health%20providers
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=1.%20Florida%3A%20The%20%22No,for%20Stimulants
• https://www.mondaq.com/unitedstates/healthcare/1447512/a-changing-regulatory-and-reimbursement-landscape-for-weight-loss-drugs#:~:text=New%20Jersey%20law%20requires%20that,and%20identify%20the%20risks%20associated
• https://drlewis.com/glp-1-medications-psychiatry/#:~:text=You%20know%20these%20drugs,disorders%2C%20and%20possibly%20depression%20itself
• https://drlewis.com/glp-1-mental-health/#:~:text=Now%20let%E2%80%99s%20talk%20about%20potential,where%20things%20get%20really%20interesting